These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 19672236)

  • 1. [Efficacy of acatinol memantine in mild cognitive disorder].
    Levin OS; Iunishchenko NA; Dudarova MA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(7):36-42. PubMed ID: 19672236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of akatinol memantine in moderate cognitive impairments.
    Levin OS; Yunishchenko NA; Dudarova MA
    Neurosci Behav Physiol; 2010 Oct; 40(8):926-33. PubMed ID: 20683775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of 12-week open-label memantine treatment on cognitive function improvement in patients with alcohol-related dementia.
    Cheon Y; Park J; Joe KH; Kim DJ
    Int J Neuropsychopharmacol; 2008 Nov; 11(7):971-83. PubMed ID: 18346293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Akatinol memantine in the therapy of cognitive disorders in Parkinson's disease].
    Puzin MN; Krivonos OV; Kozhevnikova ZhV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2007; 107(1):26-9. PubMed ID: 17310793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical features of the formation and possibilities of treatment of posttraumatic cognitive disturbances].
    Litvinenko IV; Emelin AIu; Vorob'ev SV; Lobzin VIu
    Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(12):60-6. PubMed ID: 21311490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Use of omaron in patients with post-stroke cognitive disorders].
    Parfenov VA; Belavina GR; Vakhnina NV; Gusev VV; Levin IaI; Markin SP; Starchina IuA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(6):41-5. PubMed ID: 19672226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained effects of once-daily memantine treatment on cognition and functional communication skills in patients with moderate to severe Alzheimer's disease: results of a 16-week open-label trial.
    Schulz JB; Rainer M; Klünemann HH; Kurz A; Wolf S; Sternberg K; Tennigkeit F
    J Alzheimers Dis; 2011; 25(3):463-75. PubMed ID: 21471647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The use of lucetam for improvement of cognitive functions in chronic cerebrovascular insufficiency (clinical and encephalographic study)].
    Bugrova SG; Novikov AE
    Zh Nevrol Psikhiatr Im S S Korsakova; 2007; 107(4):44-8. PubMed ID: 18379503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cognitive enhancement effect of piracetam in patients with mild cognitive impairment and dementia].
    Tariska P; Paksy A
    Orv Hetil; 2000 May; 141(22):1189-93. PubMed ID: 10853348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Memantine (akatinol) therapy of cognitive impairment in Parkinson's disease complicated by dementia].
    Litvinenko IV; Odinak MM; Mogil'naia VI; Perstenev SV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(10):37-42. PubMed ID: 19008850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Efficacy and safety of memantine in dementia with Lewy bodies].
    Levin OS; Batukaeva LA; Smolentseva IG; Amosova NA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(5):39-46. PubMed ID: 18577956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Domain-specific improvement of cognition on memantine in patients with Alzheimer's disease treated with rivastigmine.
    Riepe MW; Adler G; Ibach B; Weinkauf B; Tracik F; Gunay I
    Dement Geriatr Cogn Disord; 2007; 23(5):301-6. PubMed ID: 17356273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Akatinol memantine in patients with vascular cognitive disorders].
    Gudkova AA; Sorokina IB; Iakovlev AA; Guliaeva NV; Gekht AB
    Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(12):37-40. PubMed ID: 21311485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial.
    Aarsland D; Ballard C; Walker Z; Bostrom F; Alves G; Kossakowski K; Leroi I; Pozo-Rodriguez F; Minthon L; Londos E
    Lancet Neurol; 2009 Jul; 8(7):613-8. PubMed ID: 19520613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Efficacy and tolerability of choline alphoscerate (cereton) in patients with Parkinson's disease with cognitive disorders].
    Levin OS; Batukaeva LA; Anikina MA; Iunishchenko NA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(11):42-6. PubMed ID: 20032953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Memantine treatment of cognitive symptoms in mild to moderate Alzheimer disease: secondary analyses from a placebo-controlled randomized trial.
    Pomara N; Ott BR; Peskind E; Resnick EM
    Alzheimer Dis Assoc Disord; 2007; 21(1):60-4. PubMed ID: 17334274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Memantine and HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study.
    Schifitto G; Navia BA; Yiannoutsos CT; Marra CM; Chang L; Ernst T; Jarvik JG; Miller EN; Singer EJ; Ellis RJ; Kolson DL; Simpson D; Nath A; Berger J; Shriver SL; Millar LL; Colquhoun D; Lenkinski R; Gonzalez RG; Lipton SA; ; ;
    AIDS; 2007 Sep; 21(14):1877-86. PubMed ID: 17721095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Memantine on Cognitive Performance in Patients Under Electroconvulsive Therapy: A Double-Blind Randomized Clinical Trial.
    Alizadeh NS; Maroufi A; Jamshidi M; Hassanzadeh K; Gharibi F; Ghaderi E
    Clin Neuropharmacol; 2015; 38(6):236-40. PubMed ID: 26536019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial.
    Freund-Levi Y; Eriksdotter-Jönhagen M; Cederholm T; Basun H; Faxén-Irving G; Garlind A; Vedin I; Vessby B; Wahlund LO; Palmblad J
    Arch Neurol; 2006 Oct; 63(10):1402-8. PubMed ID: 17030655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Memantine induces reversible neurologic impairment in patients with MS.
    Villoslada P; Arrondo G; Sepulcre J; Alegre M; Artieda J
    Neurology; 2009 May; 72(19):1630-3. PubMed ID: 19092106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.